skip to main content
Show Results with:

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

Reichegger, Hermann et al.

Oncology research and treatment. Volume 39:Issue 7/8 (2016); pp 461-463 -- S. Karger AG

Online access

  • Title:
    Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
  • Author: Reichegger, Hermann;
    Jochum, Wolfram;
    Förbs, Diana;
    Hader, Claudia;
    Früh, Martin
  • Found In: Oncology research and treatment. Volume 39:Issue 7/8 (2016); pp 461-463
  • Journal Title: Oncology research and treatment
  • Subjects: AZD9291--Osimertinib--Intracranial--Lung cancer--Response--EGFR mutation--T790M; Dewey: 616.994005
  • Rights: Licensed
  • Publication Details: S. Karger AG
  • Abstract:

    Background: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Case Report: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. Conclusion: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed.


  • Identifier: System Number: ETOCvdc_100084881655.0x000001; Journal ISSN: 2296-5270; 10.1159/000446759
  • Publication Date: 2016
  • Physical Description: Electronic
  • Shelfmark(s): 6256.983450
  • UIN: ETOCvdc_100084881655.0x000001

Searching Remote Databases, Please Wait